open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22
Get Citation

Non-pegylated liposomal doxorubicin use in the treatment of bilateral breast cancer

Monika Nowaczyk

open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22

Abstract

Breast cancer is the most common cancer between women. It is the most common cancer among residents of USA, Canada, Australia and West Europe. Metastatic breast cancer is an incurable disease. Women with metastatic breast cancer are treated with systemic therapy. In this phase of the disease treatment is palliative and its aim is to prolong and improve the quality of life. Not yet determined the optimal first-line treatment regimen. The selection should take into account the effectiveness and adverse event profile depending on the individual characteristics of patients. The most active biological agents used to treat breast cancer are anthracyclines. The use of anthracyclines is limited by their cardiotoxicity mainly as a consequence of triggering of congestive heart failure. Currently, there is a possibility to re-apply after the introduction of liposomal anthracyclines form of these drugs.
Onkol. Prak. Klin. 2010; supl. A: A40–A42

Abstract

Breast cancer is the most common cancer between women. It is the most common cancer among residents of USA, Canada, Australia and West Europe. Metastatic breast cancer is an incurable disease. Women with metastatic breast cancer are treated with systemic therapy. In this phase of the disease treatment is palliative and its aim is to prolong and improve the quality of life. Not yet determined the optimal first-line treatment regimen. The selection should take into account the effectiveness and adverse event profile depending on the individual characteristics of patients. The most active biological agents used to treat breast cancer are anthracyclines. The use of anthracyclines is limited by their cardiotoxicity mainly as a consequence of triggering of congestive heart failure. Currently, there is a possibility to re-apply after the introduction of liposomal anthracyclines form of these drugs.
Onkol. Prak. Klin. 2010; supl. A: A40–A42
Get Citation

Keywords

non-pegylated liposomal doxorubicin; metastatic breast cancer

About this article
Title

Non-pegylated liposomal doxorubicin use in the treatment of bilateral breast cancer

Journal

Oncology in Clinical Practice

Issue

Vol 6, Supp. A (2010)

Pages

40-42

Published online

2010-11-22

Keywords

non-pegylated liposomal doxorubicin
metastatic breast cancer

Authors

Monika Nowaczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl